GET DAILY SIGNALSChemomab Therapeutics (CMMB) Climbs +19% on Scipher Medicine Merger Progress
Key Takeaways
- CMMB shares climbed roughly 19% over the trailing 30 days, rebounding from a late-October low near $1.00 to a recent close of $1.53.
- The advance coincided with meaningful progress on the company's planned merger with precision medicine firm Scipher Medicine.
- The SEC declared the merger registration statement effective in late October, clearing a key step toward the transaction.
- Over the trailing quarter, however, the stock remains down about 20%, reflecting a sharp late-September selloff from above $2.00.
- Chemomab remains a pre-revenue, clinical-stage biotech, making the shares highly sensitive to clinical, regulatory, and financing milestones.
- A special shareholder meeting to vote on the proposed merger is scheduled for December 4, 2026.
- For additional detail on the stock, explore its Price Targets, Earnings, and Forecast pages.
Company Background and Strategic Direction
Chemomab Therapeutics Ltd. is a clinical-stage biotechnology company focused on therapies for fibrotic and inflammatory diseases with significant unmet needs. Its lead candidate, nebokitug, is a first-in-class monoclonal antibody designed to neutralize CCL24, a key regulator of fibrosis and inflammation. The company has shared results from trials including the Phase 2 SPRING study in primary sclerosing cholangitis and evaluations in systemic sclerosis.
Attention has shifted toward the company’s strategic move to merge with Scipher Medicine. This combination would pair nebokitug with Scipher’s AI-driven precision medicine platform for a biomarker-guided Phase 2 trial in rheumatoid arthritis. As a pre-revenue firm with a modest market cap, CMMB valuation hinges on clinical progress, financing events, and transaction milestones rather than current earnings. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Stock Performance: 30-Day Rebound Against Quarterly Weakness
Over the past 30 days, CMMB shares advanced roughly 19%, rising from a mid-October close near $1.29 to $1.53 in the most recent session. This marked a recovery from a late-October low around $1.00, with renewed interest building ahead of merger milestones.
The quarterly view tells a different story. From a mid-August close near $1.90, the stock is down about 20% over three months. Much of that decline came in a sharp late-September selloff that took shares from above $2.00 into the $1.20 area. The recent 30-day gain therefore represents a partial recovery from a deeper pullback rather than the start of a sustained uptrend.
Factors Behind the Recent Advance
The move higher ties closely to concrete steps on the Scipher Medicine merger. In late October the SEC declared the registration statement effective, and in early November the company announced a special shareholder meeting for December 4, 2026 to vote on the deal. Proxy materials filed in mid-November provided further governance details. These developments clarified the path forward and appeared to support buying interest.
The rebound followed heavy selling earlier, with elevated volumes in late September and late October. Bargain hunting and a clearer merger timeline both played roles. Market coverage includes a Buy rating with a $5.00 price target, though the shares continue to trade well below that level given ongoing execution and financing risks.
Quarterly Drivers and Structural Considerations
Over the trailing quarter, performance has been shaped more by the merger and restructuring narrative than by fresh clinical data. After a run-up into late August around second-quarter results and conference presentations, the stock sold off sharply in late September. Investors focused on dilution and ownership shifts, with former Chemomab holders expected to own about 32% of the combined company and certain former Scipher securityholders about 68%.
Subsequent filings outlined amendments to the domestication merger, including adjustments to the post-merger share count and revised contingent value rights terms. The combined entity plans to pursue a Nasdaq listing under a new ticker once the deal closes. These changes have kept volatility elevated as the market weighs the potential of the precision medicine platform against the complexities of completing the cross-border transaction.
Upcoming Catalysts and Risks to Monitor
The December 4, 2026 special shareholder meeting stands out as the nearest major catalyst. The vote outcome, along with any updates on closing conditions, financing, and the planned Nasdaq listing, should dominate sentiment in the coming weeks.
Further out, investors will track progress on the planned AI-powered Phase 2 trial of nebokitug in rheumatoid arthritis and any additional data from the Phase 2 SPRING program in primary sclerosing cholangitis. Cash runway, dilution, and financing developments remain key risks for this pre-revenue company. Broader market conditions affecting small-cap biotech names could also influence trading.
AI Tools Supporting My Research
In my analysis, I frequently consult Tickeron’s AI Trading Bots to review systematic, data-driven approaches across equities. The platform offers hundreds of automated strategies that monitor thousands of tickers, with top performers highlighted for easier comparison. This helps place names like CMMB in a broader context of market behavior without replacing traditional fundamental review.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
CMMB's MACD Histogram just turned positive
The Moving Average Convergence Divergence (MACD) for CMMB turned positive on October 27, 2026. Looking at past instances where CMMB's MACD turned positive, the stock continued to rise in 34 of 39 cases over the following month. The odds of a continued upward trend are 87%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on November 02, 2026. You may want to consider a long position or call options on CMMB as a result. In 61 of 75 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 81%.
Following a +13.33% 3-day Advance, the price is estimated to grow further. Considering data from situations where CMMB advanced for three days, in 195 of 231 cases, the price rose further within the following month. The odds of a continued upward trend are 84%.
Bearish Trend Analysis
The RSI Oscillator demonstrated that the stock has entered the overbought zone. This may point to a price pull-back soon.
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 6 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
The 50-day moving average for CMMB moved below the 200-day moving average on November 10, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where CMMB declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
CMMB broke above its upper Bollinger Band on November 13, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for CMMB entered a downward trend on November 04, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 29 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 42 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.114) is normal, around the industry mean (3.498). P/E Ratio (-1.375) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 62 (best 1 - 100 worst), indicating steady price growth. CMMB’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CMMB’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a provider of biopharmaceutical services
Industry Biotechnology
Advertisement